GENE ONLINE|News &
Two River and Vida Ventures Achieve Success as UCB Acquires Candid Therapeutics
Two River and Vida Ventures recently broadened their history of establishing companies and realizing value after UCB acquired Candid Therapeutics. The acquisition highlights the success of Two River and Vida Ventures’ strategy of identifying promising scientific advancements and building companies around them.
Two River and Vida Ventures focus on supporting innovative research and development. Their collaborative approach provides companies with the resources and expertise needed to advance groundbreaking therapies. The acquisition of Candid Therapeutics by UCB marks another milestone in their commitment to fostering innovation and delivering value in the healthcare sector.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: May 4, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Digitalis Glycosides Studied for Heart Failure Treatment at ESC Heart Failure 2026 Congress
2026-05-10
Digoxin Lowers Death Risk and Heart Failure in Rheumatic Heart Disease Patients, Study Finds
2026-05-10
New Test Detects Biomarkers for Frontotemporal Lobar Degeneration, a Rare Dementia Affecting Over 57 Million Globally
2026-05-10
